title: Relationship between p73 polymorphism and the immunohistochemical profile of the full-length (TAp73) and NH2-truncated (ΔNp73) isoforms in Tunisian patients.
abstract: BACKGROUND
  We examined the association of one linked GC/AT polymorphism at p73 with the risk of colorectal cancer.
  
  
  OBJECTIVE
  In this study, we investigated whether this polymorphism was related to the risk of colorectal cancer, and whether there were relationships between the polymorphism and loss of heterozygosity, protein expression, or clinicopathologic variables.
  
  
  METHODS
  The p73 genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism in 150 Tunisian patients with colorectal cancer and in 204 healthy control subjects. Immunohistochemistry was performed on normal mucosa, primary tumor, and metastasis.
  
  
  RESULTS
  The frequencies of the genotypes were 52% for wild-type (GC/GC), 31% for heterozygotes (GC/AT), and 17% for variants(AT/AT) in patients, and 54%, 35%, and 11% in controls, respectively. There were no significant differences of the frequencies of the 3 genotypes between the patients and controls (P=0.11). We did not find any relationship of the genotypes with clinicopathologic features of patients. We found that patients with the GC/GC genotype had a significantly more favorable clinical outcome than the patients with the AT variants (AT/AT or GC/AT genotype). There were no significant difference between tumoral immunostaining and p73 polymorphism (P=0.16) but we found that the samples carrying the AT allele showed a tendency to be more stained in tumor. No loss of heterozygosity was observed at p73 locus. Our results suggest that the AT/AT genotype is significantly associated with poor prognosis in colorectal cancer. All these findings suggest that p73 polymorphism analysis may provide useful prognostic information for colorectal cancer patients.
authors: Laboratory of Colorectal Cancer Research UR03ES04, Science University Tunis, Tunisia. arfaouiamira@hotmaill.com
authors: Amira Toumi
authors: AT
authors: Arfaoui
authors: Lilia Kriaa
authors: LK
authors: Ben Mahmoud
authors: Abdelmajid
authors: A
authors: Ben Hmida
authors: Mariem
authors: M
authors: Khiari
authors: Amine Lounis
authors: AL
authors: Mohamed
authors: Ines
authors: I
authors: Chaar
authors: Taher
authors: T
authors: Khalfallah
authors: Sabeh Mzabi
authors: SM
authors: Regaya
authors: Saadia
authors: S
authors: Bouraoui
mesh_terms: D016022:Case-Control Studies; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D004268:DNA-Binding Proteins / Q000235:genetics; D005260:Female; D056726:Genetic Association Studies; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D007413:Intestinal Mucosa / Q000503:physiopathology / Q000648:ultrastructure*; D053208:Kaplan-Meier Estimate; D019656:Loss of Heterozygosity; D008297:Male; D009687:Nuclear Proteins / Q000235:genetics*; D012150:Polymorphism, Restriction Fragment Length / Q000235:genetics*; D011379:Prognosis; D020033:Protein Isoforms / Q000235:genetics*; D012189:Retrospective Studies; D012307:Risk Factors; D000072160:Tumor Protein p73; D025521:Tumor Suppressor Proteins / Q000235:genetics; D014416:Tunisia
chemical_list: D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; D020033:Protein Isoforms; C000606460:TP73 protein, human; D000072160:Tumor Protein p73; D025521:Tumor Suppressor Proteins; C000606369:delta Np73 protein, human